A high-risk, speculative long trade was suggested on an asset referred to as "Octo", though a specific ticker was not provided. The investment thesis is not based on fundamentals but on identifying a potential "glitch in the market" due to perceived irrationality. This strategy is compared to a previously successful trade in SBEP that was based on a similar premise of exploiting market inefficiency. While this type of trade is highly speculative, it highlights a strategy of looking for illogical market situations as potential opportunities. As a cautionary note from the Celgene case study, investors should always assess single-product dependency and patent cliffs when analyzing companies.

"Octo" (Ticker Not Specified)

• The speaker expressed a bullish sentiment, stating, "something like Octo, I would go long."
• The investment thesis is highly speculative and based on market irrationality rather than company fundamentals. The speaker's reasoning is that the investment is "so fucking stupid" that it represents a potential "glitch in the market."
• This strategy is compared to a past successful trade in SBEP, which the speaker notes "worked" on a similar premise.

Takeaways

• This is a high-risk, speculative trade idea. The speaker is betting on market inefficiency and irrationality, not on the underlying value of the asset.
• The insight is that sometimes opportunities can be found in assets or situations that seem illogical to the broader market.
• Investors should be aware that this type of "glitch" trade is not a fundamental investment strategy and carries a significant risk of loss. The ticker for "Octo" was not specified.

Celgene (Historical Case Study)

• Celgene is discussed as a historical case study for biotech investors. It was acquired by Bristol Myers Squibb (BMY).
• The company had a massive hit product, Revlimid, which had a potential market ceiling of $60 billion to $80 billion.
• Despite this success, the company struggled because it "could never get past the Revlimid ceiling," highlighting the danger of being dependent on a single product.
• A major challenge for Celgene was its intellectual property (IP) situation, which made its long-term revenue from Revlimid uncertain.

Takeaways

• This serves as a cautionary tale for investors in the pharmaceutical and biotech sectors.
• When analyzing a biotech company, it's crucial to look beyond its current blockbuster drug. Pay close attention to:
  • Single-product risk: How much of the company's revenue comes from one drug?
  • Drug pipeline: Does the company have other promising drugs in development to ensure future growth?
  • Patent cliffs: When does the intellectual property (IP) for its main drugs expire? Expiring patents open the door to generic competition, which can decimate revenue.

Abivax (ABVX)

• Abivax was mentioned briefly at the start of the podcast.
• The speaker wondered if the company was currently holding an earnings call but provided no further context, opinion, or analysis on the company or its stock.

Takeaways

• There were no actionable investment insights or opinions provided for Abivax. It was only a passing mention.